The Genomic Era:
Genomic Diagnostic Tests herald a significant breakthrough in the move away from one size fits all cancer medicine still common in most hospitals today:
Following on from the mapping of the human genome, just 14 years ago, genomic diagnostic and screening tests can now accurately identify targeted treatments for cancer patients.
These tests lay the foundation for precision medicine, also called personalised or targeted medicine.
As well as genomic diagnostic tests, we also help our patients access pharmacogenomic tests, a blend of pharmacy & genomics. These tests determine whether the patient can metabolise (digest/absorb) the identified target treatment successfully.
The two tests have revolutionised cancer medicine leading to targeted treatments achieving better outcomes with minimal side effects.
Cancer patients now have a choice between the old & new cancer technologies…
Patients on our Cancer Navigation Package can significantly boost health restoration outcomes via our referrals to world-class genomic diagnostic testing leading to accurately targeted treatments
Despite recent advances, the outdated one size fits all model is still common in conventional medicine as well as complementary & alternative cancer medicines.
Sadly one size fits all approaches are still commonplace in…
- Our hospitals – this is the Gold Standard of Cancer Care. Hospitals are limited by finances & hospital/insurance company protocols.
- Supplements, super-foods or extreme diet approaches erroneously assume patients are genetically the same and all metabolise essential ingredients & constituents similarly.
- Generic advice from Dr Google, family, friends, workmates is by nature, one size fits all, and may do more harm than good, can eve cause or accelerate cancer.
The following quote from Genome Mag explains how the old one size fits all medicine works:
“Most often today, your treatment plan isn’t about you specifically. It’s what doctors would give to anyone with the same condition — your neighbour, the hot dog vendor, or the prime minister of Bangladesh. Most cancer medicine revolves around “standards of care,” that is providing the best courses of prevention or treatment for the average person on the street.
With breast cancer, for example, those standards mean self-exams and mammograms after a set age and the usual chemotherapy, surgery to treat a tumour if one is found.If the first treatment doesn’t work, doctors and patients move on to the next one and the next. It’s trial and error, with life on the line.
But each cancer in each person has its own genetic makeup – each tumour is a unique character with unique tendencies and vulnerabilities. In some cases, the current standard of care may be the safest, most sensible option, but it’s also one size fits all.
Sometimes that’s sufficient, but not always.”
Testimonial to the new cancer technologies.
The patient, Jeffrey Deslandes, with cancer navigator Grace Gawler, (below) is a 12 year survivor of stage IV non-Hodgkin’s lymphoma.
Jeffrey is cancer free because he researched & embraced cancer vaccines delivered by a doctor in Brisbane. Impressed by Jeffrey’s results, we began referring patients to his doctor until he lost his these research funding.
We thought this new technology was worth persevering with – So we went to the source.
The Brisbane doctor had learned the cancer vaccine method in Japan and was sending patient’s bloods to a lab in Japan for modifying.
We began a dialogue with them and the leading doctor who is an most impressive cancer pioneer. As the world leader of the technology, he has 100s of medical journal papers to his name and has successfully used the vaccines with over 10,000 patients since the 1990’s.
May 2018: We have now been working closely with him for nearly 4 years. Via this collaboration, our patients can now access advanced cancer vaccines, even more comprehensive than the ones Jeffrey received in Brisbane. The outcomes have been exceptional for almost all patients.
Added Effectiveness: The cancer vaccines (immune therapies) become even more effective when used in conjunction with other high-tech treatments. These include hyperthermia, low-dose radiation, low dose chemotherapy, Gamma knife, Cyber Knife, Proton Beam Therapy and even surgery. You will see on the chart below, when it comes to new cancer technologies, countries like Australia, UK, Canada or New Zealand lag behind other OECD countries.
Via our global cancer navigation service, we can often access these new medicines for our patients once they are approved overseas. We know it can be many years before they become available in Australia or NZ, for example.
As well, we can help our patients access precision or personalised medicine built around genomic and pharmaco-genomic tests.
Our testimonial page (blue button below) features 10 remarkable patient stories – all recipients of precision or personalised medicine.
Australian & New Zealand Cancer Patients are missing out on a second chance at life compared to other OECD countries
There’s even more good news for our patients:
We mentioned pharmacogenomics at the top of the page.
Pharmacogenomics is the study of the role of the genome in drug response.
It gets its name (pharmaco- + genomics) asesult of combining pharmacology and genomics.
Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her response to drugs.
So if your genomic diagnostic test identifies some target treatments, the pharmacogenomic test will indicate your ability to metabolise them. You would avoid medicines you can’t metabolise well (they also give worse side effects for you).
This process ensures you get the treatment best suited to your genetic type. A more effective approach to the trial an error methods still widely used in most hospitals.